2026-10-22 13:49:00 UTC#500470newconfirmednews
AMRX stock news
AMRX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire15 wire items
2026-09-23 12:20:00 UTC#355322newconfirmednews
Oppenheimer initiates Amneal Pharmaceuticals (AMRX) at Outperform with $27 price target
2026-09-21 11:28:15 UTC#341971duplicateconfirmednews
Amneal Pharmaceuticals shares rise following FDA approval of generic lanreotide
tradingviewimportance 0.30trust 0.50Amneal Pharmaceuticals, Inc. +0.60Ipsen S.A. -0.50Food and Drug Administration 0
2026-09-21 10:17:00 UTC#341441newconfirmednews
Ipsen shares drop 6.6% as FDA approves Amneal's generic Somatuline earlier than expected
dow_jonesimportance 0.60trust 0.80Ipsen S.A. -0.70Amneal Pharmaceuticals, Inc. +0.50U.S. Food and Drug Administration -0.20+2 entities
2026-08-27 13:03:00 UTC#229258duplicateconfirmedanalysis
Yahoo recommends defensive stocks COCO, DAR, CNC, EXC, and AMRX following August consumer confidence decline
yahooimportance 0.30trust 0.40The Vita Coco Company, Inc. +0.30Darling Ingredients Inc. +0.30Centene Corporation +0.30+2 entities
2026-08-26 14:10:00 UTC#223535newconfirmednews
JPMorgan sets $22.00 price target on Amneal Pharmaceuticals (AMRX)
2026-08-10 12:01:00 UTC#152441newconfirmedpress release
Amneal Pharmaceuticals completes acquisition of Kashiv BioSciences to expand biosimilar portfolio
2026-08-03 19:57:00 UTC#118772newconfirmednews
UBS maintains Buy on Amneal Pharmaceuticals, raises price target to $25 from $23
2026-07-31 13:40:52 UTC#109822newconfirmednews
Amneal Pharmaceuticals (AMRX) shareholders approve acquisition of Kashiv BioSciences and share issuance
2026-07-30 18:25:11 UTC#104040duplicateconfirmednews
Amneal Pharmaceuticals reiterates 2026 revenue guidance of $3.1B-$3.2B, sets capex at $150M
2026-07-30 16:13:13 UTC#103329duplicateconfirmednews
Amneal Pharmaceuticals Q2 adjusted EPS $0.30 vs $0.22 estimate, revenue $796.2M vs $768.2M expected
2026-07-30 10:27:25 UTC#100757duplicateconfirmednews
Amneal Pharmaceuticals (AMRX) Q2 2026 Revenue Up 10%, EBITDA Up 12% With Raised Full-Year Guidance
2026-07-30 10:18:14 UTC#100698newconfirmednews
Amneal Q2 revenue and EPS beat expectations; raises 2026 revenue guidance to $3.10B-$3.20B
reutersimportance 0.60trust 0.90Amneal Pharmaceuticals, Inc. +0.60CREXONT +0.50BREKIYA +0.50+1 entities
2026-07-29 14:45:47 UTC#94929newforecastanalysis
Amneal Pharmaceuticals Q2 2026 Earnings Preview
2026-07-08 12:03:01 UTC#12087newconfirmednews